Clinical and Translational Research
Copyright ©The Author(s) 2021.
World J Hepatol. Feb 27, 2021; 13(2): 218-232
Published online Feb 27, 2021. doi: 10.4254/wjh.v13.i2.218
Table 1 Demographic and clinical data of chronic hepatitis C patients compared with healthy individuals
CHC, n = 119CT, n = 119P value
Sex, n (%)< 0.001
Men53 (45)75 (63)
Women66 (55)44 (37)
Age in yr54 ± 1337 ± 10< 0.001
BMI in kg/m227 ± 128 ± 10.340
Hb in g/dL14 ± 216 ± 1< 0.001
Leu as 103/µL5.1 ± 1.07.4 ± 0.2< 0.001
Platelets as × 103177 ± 78272 ± 62< 0.001
Total bilirubin in mg/dL2.52 ± 1.700.75 ± 0.290.001
Direct bilirubin in mg/dL0.18 ± 0.150.07 ± 0.060.001
AST in UI/L60 ± 530 ± 11< 0.001
ALT in UI/L63 ± 526 ± 18< 0.001
GGT in UI/L92.50 ± 10.6730.55 ± 2.43< 0.001
Table 2 Demographic and biochemical data according to fibrosis stages
F0 (36)F1 (11)F2 (14)F3 (20)F4 (38)Differences
Sex, n (%)
Men10 (30)6 (60)7 (50)9 (45)13 (37)N/A
Women26 (70)5 (40)7 (50)11 (55)25 (63)N/A
Age in yr50 ± 1239 ± 755 ± 1359 ± 1055 ± 13F0-F1a, F0-F3a, F1-F2b, F1-F3b, F1-F4b
BMI in kg/m225 ± 426 ± 426 ± 327 ± 327 ± 5F0-F4a
Hb in g/dL15.0 ± 1.314.0 ± 2.014.0 ± 2.014.0 ± 2.014.0 ± 2.0N/S
Leu in g/dL5.6 ± 1.36.5 ± 0.84.2 ± 1.44.7 ± 1.24.3 ± 2.2F0-F4b
Platelets as × 103231 ± 56233 ± 20193 ± 74163 ± 5492 ± 39F0-F3b
F0-F4b
F1-F4b
F2-F4b
F3-F4b
Total bilirubin in mg/dL0.72 ± 0.310.44 ± 0.220.73 ± 0.281.75 ± 0.852.39 ± 2.7F0-F1b
F1-F4b
F2-F4a
F3-F4a
Direct bilirubin in mg/dL0.18 ± 0.100.07 ± 0.050.12 ± 0.100.23 ± 0.150.27 ± 0.3F0-F1a
AST in UI/L45 ± 738 ± 1249 ± 1174 ± 1086 ± 16F0-F3b
F0-F4b
F1-F3a
F1-F4a
ALT in UI/L56 ± 1156 ± 857 ± 1069 ± 1080 ± 13F0-F4b
GGT in UI/L70.49 ± 15.6551.30 ± 19.4352.62 ± 14.1091.58 ± 18.74144.00 ± 25.29F0-F4a
F1-F3a
F1-F4b
F2-F4a

  • Citation: Martinez-Castillo M, Hernandez-Barragan A, Flores-Vasconcelos I, Galicia-Moreno M, Rosique-Oramas D, Perez-Hernandez JL, Higuera-De la Tijera F, Montalvo-Jave EE, Torre-Delgadillo A, Cordero-Perez P, Muñoz-Espinosa L, Kershenobich D, Gutierrez-Reyes G. Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients. World J Hepatol 2021; 13(2): 218-232
  • URL: https://www.wjgnet.com/1948-5182/full/v13/i2/218.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v13.i2.218